BACKGROUND: We examined the trend in prevalence of high-risk human papillomavirus (hrHPV) cervical infection among Rwandan women living with HIV (WLWH) over 12 years. METHODS: Prevalence of cervical hrHPV DNA was measured in 3 studies at 3 different time periods in 3 different groups of WLWH using 3 different but comparable hrHPV tests: a MY09/MY11 PCR test in 2005 (RWISA; n = 497), careHPV in 2009-2010 (HPV Demonstration; n = 1242), and Xpert HPV test in 2016-2018 (U54; n = 4734). Prevalences were adjusted for age and CD4 cell count. RESULTS: HrHPV prevalence decreased over time from 42.5% to 32.2% to 26.5% (P < .001). CD4 cell counts improved over time (Ptrend <.001) so that the percentage of WLWH with CD4 counts of ≥500 cells/μL increased from 7.7% in 2005 to 42.2% in 2009-2010 and 61.1% in 2016-2018. Thus, after adjustment for differences in CD4 counts and age, hrHPV prevalences were more similar over time: 32.6% for RWISA, 30.6% for HPV Demonstration, and 27.1% for U54 (P = .007). CONCLUSIONS: Prevalence of hrHPV among WLWH has decreased over the past decade, most likely the result of improved immune reconstitution due to better HIV care and management in Rwanda.
BACKGROUND: We examined the trend in prevalence of high-risk human papillomavirus (hrHPV) cervical infection among Rwandan women living with HIV (WLWH) over 12 years. METHODS: Prevalence of cervical hrHPV DNA was measured in 3 studies at 3 different time periods in 3 different groups of WLWH using 3 different but comparable hrHPV tests: a MY09/MY11 PCR test in 2005 (RWISA; n = 497), careHPV in 2009-2010 (HPV Demonstration; n = 1242), and Xpert HPV test in 2016-2018 (U54; n = 4734). Prevalences were adjusted for age and CD4 cell count. RESULTS: HrHPV prevalence decreased over time from 42.5% to 32.2% to 26.5% (P < .001). CD4 cell counts improved over time (Ptrend <.001) so that the percentage of WLWH with CD4 counts of ≥500 cells/μL increased from 7.7% in 2005 to 42.2% in 2009-2010 and 61.1% in 2016-2018. Thus, after adjustment for differences in CD4 counts and age, hrHPV prevalences were more similar over time: 32.6% for RWISA, 30.6% for HPV Demonstration, and 27.1% for U54 (P = .007). CONCLUSIONS: Prevalence of hrHPV among WLWH has decreased over the past decade, most likely the result of improved immune reconstitution due to better HIV care and management in Rwanda.
Authors: Howard D Strickler; Jeffrey Martinson; Seema Desai; Xianhong Xie; Robert D Burk; Kathryn Anastos; L Stewart Massad; Howard Minkoff; Xiaonan Xue; Gypsyamber D'Souza; Alexandra M Levine; Christine Colie; D Heather Watts; Joel M Palefsky; Alan Landay Journal: Viral Immunol Date: 2014-02 Impact factor: 2.257
Authors: Diljeet K Singh; Kathryn Anastos; Donald R Hoover; Robert D Burk; Qiuhu Shi; Louis Ngendahayo; Eugene Mutimura; Antonio Cajigas; Venerand Bigirimani; Xiaotao Cai; Janvier Rwamwejo; Magalis Vuolo; Mardge Cohen; Philip E Castle Journal: J Infect Dis Date: 2009-06-15 Impact factor: 5.226
Authors: Philip E Castle; Attila T Lorincz; David R Scott; Mark E Sherman; Andrew G Glass; Brenda B Rush; Sholom Wacholder; Robert D Burk; M Michele Manos; John E Schussler; Paul Macomber; Mark Schiffman Journal: J Clin Microbiol Date: 2003-09 Impact factor: 5.948
Authors: D Scott LaMontagne; Paul J N Bloem; Julia M L Brotherton; Katherine E Gallagher; Ousseynou Badiane; Cathy Ndiaye Journal: Int J Gynaecol Obstet Date: 2017-07 Impact factor: 3.561
Authors: Fidele Ngabo; Silvia Franceschi; Iacopo Baussano; M Chantal Umulisa; Peter J F Snijders; Anne M Uyterlinde; Fulvio Lazzarato; Vanessa Tenet; Maurice Gatera; Agnes Binagwaho; Gary M Clifford Journal: BMC Infect Dis Date: 2016-05-24 Impact factor: 3.090
Authors: J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray Journal: Int J Cancer Date: 2018-12-06 Impact factor: 7.396
Authors: Gad Murenzi; Fabienne Shumbusho; Natasha Hansen; Athanase Munyaneza; Julia C Gage; Benjamin Muhoza; Faustin Kanyabwisha; Amanda Pierz; Patrick Tuyisenge; Kathryn Anastos; Philip E Castle Journal: BMJ Open Date: 2022-08-25 Impact factor: 3.006